Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol 2010 Sep;63(3):457-65
Date
05/14/2010Pubmed ID
20462664DOI
10.1016/j.jaad.2009.09.014Scopus ID
2-s2.0-77955921585 (requires institutional sign-in at Scopus site) 182 CitationsAbstract
BACKGROUND: Anxiety, depression, and impaired health-related quality of life (HRQoL) are common in patients with psoriasis.
OBJECTIVE: We sought to analyze the effect of ustekinumab on these conditions in patients with moderate-to-severe psoriasis.
METHODS: Patients with moderate-to-severe psoriasis (n = 1230) were randomized 1:1:1 to receive 45 mg of ustekinumab, 90 mg of ustekinumab, or placebo. The Hospital Anxiety and Depression Scale was used to measure anxiety and depression, and the Dermatology Life Quality Index to measure HRQoL.
RESULTS: At baseline, 40.3% and 26.7% of patients reported symptoms of anxiety and depression, respectively, and 54.6% reported Dermatology Life Quality Index scores greater than 10, indicating a very high impact of disease on HRQoL. Greater improvements at week 12 in mean Hospital Anxiety and Depression Scale-Anxiety (13.9%), Hospital Anxiety and Depression Scale-Depression (29.3%), and Dermatology Life Quality Index (76.2%) scores were reported in ustekinumab groups compared with placebo (P < .001 each).
LIMITATIONS: Results for these measures are reported only through 24 weeks.
CONCLUSION: Patients receiving ustekinumab reported significant improvements in symptoms of anxiety, depression, and HRQoL.
Author List
Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, Ortonne JP, Gordon KB, Kimball ABAuthor
Kenneth Brian Gordon MD Chair, Professor in the Dermatology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAntibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Anxiety
Depressive Disorder
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Female
Humans
Male
Middle Aged
Psoriasis
Quality of Life
Reference Values
Severity of Illness Index
Treatment Outcome
Ustekinumab